Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has maintained a 'Hold' rating on Sage Therapeutics (NASDAQ:SAGE) and lowered the price target from $40 to $20.
August 08, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics' price target has been lowered from $40 to $20 by Truist Securities, which maintains a 'Hold' rating on the stock.
The lowering of the price target for Sage Therapeutics by Truist Securities indicates a less optimistic outlook for the stock, which could negatively impact its short-term price. The 'Hold' rating suggests that the stock is not expected to outperform in the near future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100